5-Cyclohexyl-1-(5-(N-ethyl-N-phenylmethylamino)pentyl)-1H-indole-2,3-dione | 162400-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Cyclohexyl-1-(5-(N-ethyl-N-phenylmethylamino)pentyl)-1H-indole-2,3-dione
• 英文别名: 1-[5-[Benzyl(ethyl)amino]pentyl]-5-cyclohexyl-indoline-2,3-dione；1-[5-[benzyl(ethyl)amino]pentyl]-5-cyclohexylindole-2,3-dione
• CAS: 162400-59-1
• 化学式: C₂₈H₃₆N₂O₂
• 分子量: 432.606
• InChiKey: RLCCRJVHOVASFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Agents and crystals for improving excretory potency of urinary bladder
  申请人：——

  公开号：US20020177593A1

  公开（公告）日：2002-11-28

  Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

  改善膀胱功能的药剂，包括一种非卡巴酯类胺化合物，具有乙酰胆碱酯酶抑制作用。特别地，提供了一种三环、紧凑、杂环衍生物的晶体，具有优异的抑制乙酰胆碱酯酶作用和改善膀胱排泄功能的作用。例如，揭示了8-[3-[1-[(3-氟苯基)-甲基]-4-哌啶基]-1-氧代丙基]-1,2,5,6-四氢-4H-吡咯烷[3,2,1-ij]-喹啉-4-酮或其盐和含有它们的药物组合物。
• Cyclic compounds
  申请人：——

  公开号：US20030229089A1

  公开（公告）日：2003-12-11

  A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1 wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药理学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含有N原子的杂环环或被含有N原子的杂环环取代的羟基（每个都可以选择性地取代），R2为较低的烷基氨基基，可选择地被芳基基取代，较低的烷氧基，可选择性地被芳基基取代，被含有N原子的芳香杂环环取代的较低的烷氧基，R3为芳基、含有N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、被含有N原子的杂环环取代的羟基或氨基（每个都可以选择性地取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• Agents for improving excretory potency of urinary bladder
  申请人：——

  公开号：US20040116457A1

  公开（公告）日：2004-06-17

  Agents for improving excretory potency of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action.

  改善排泄能力的尿道代理，包括一种非卡巴酯型胺类化合物，具有乙酰胆碱酯酶抑制作用。
• DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1118322A1

  公开（公告）日：2001-07-25

  Agents for improving excretory potency of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action.

  改善膀胱排泄能力的制剂，其中包括一种具有乙酰胆碱酯酶抑制作用的非氨基甲酸酯类胺类化合物。
• CYCLIC COMPOUNDS
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP1277741A1

  公开（公告）日：2003-01-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof,    wherein X is =CH-or=N-, Y is-NH-, -NR4-, -S-, - O-, -CH=N-, -N=CH-, -N=N-, -CH=CH-, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.    The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  1.式（I）的环状化合物或其药理学上可接受的盐、 其中 X 是 =CH-or=N-, Y 是-NH-、-NR4-、-S-、-O-、-CH=N-、-N=CH-、-N=N-、-CH=CH-等、R1 是低级烷氧基、氨基、含 N 原子的杂环或被含 N 原子的杂环取代的羟基（其中每一个都可选择被取代）， R2 是低级烷基氨基，可选择被芳基取代，低级烷氧基，可选择被芳基取代、R3 是芳基、含 N 原子的杂环、低级烷基、低级烷氧基、环低级烷氧基、被含 N 原子的杂环取代的羟基或氨基（其中每个基团都可选择被取代），R3 和 Y 中的一个取代基可结合形成一个内酯环。 本发明的化合物具有优异的选择性 PDE V 抑制活性，因此可用作治疗或预防药物，用于治疗因 cGMP 信号转导功能紊乱而引起的各种疾病。